JP Morgan Chase
ADAP

JP Morgan Chase’s Adaptimmune Therapeutics ADAP Stock Holding History

JP Morgan Chase’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-22,782
Closed -$5.46K – 7360
2025
Q2 		$5.46K Sell
22,782
-859,549
-97% -$229K ﹤0.01% 6408
2025
Q1 		$174K Sell
882,331
-34,610
-4% -$17.9K ﹤0.01% 5301
2024
Q4 		$494K Sell
916,941
-128,592
-12% -$93.7K ﹤0.01% 5053
2024
Q3 		$994K Buy
1,045,533
+8,295
+0.8% +$9.41K ﹤0.01% 4473
2024
Q2 		$1.01M Buy
1,037,238
+122,208
+13% +$134K ﹤0.01% 4274
2024
Q1 		$1.45M Sell
915,030
-13,194
-1% -$15.9K ﹤0.01% 4082
2023
Q4 		$736K Sell
928,224
-103,193
-10% -$58.2K ﹤0.01% 4536
2023
Q3 		$805K Sell
1,031,417
-273,497
-21% -$230K ﹤0.01% 4206
2023
Q2 		$1.21M Buy
1,304,914
+1,071
+0.1% +$1.28K ﹤0.01% 3906
2023
Q1 		$1.42M Buy
1,303,843
+302,731
+30% +$469K ﹤0.01% 3797
2022
Q4 		$1.46M Sell
1,001,112
-5,720
-0.6% -$9.26K ﹤0.01% 3804
2022
Q3 		$1.08M Sell
1,006,832
-467,331
-32% -$859K ﹤0.01% 3932
2022
Q2 		$2.51M Buy
1,474,163
+74,398
+5% +$128K ﹤0.01% 3356
2022
Q1 		$2.88M Sell
1,399,765
-78,273
-5% -$211K ﹤0.01% 3470
2021
Q4 		$5.54M Sell
1,478,038
-118,223
-7% -$538K ﹤0.01% 2967
2021
Q3 		$8.25M Sell
1,596,261
-260,062
-14% -$1.17M ﹤0.01% 2563
2021
Q2 		$7.91M Buy
1,856,323
+170,603
+10% +$828K ﹤0.01% 2638
2021
Q1 		$8.95M Buy
1,685,720
+656,917
+64% +$3.76M ﹤0.01% 2462
2020
Q4 		$5.54M Buy
1,028,803
+560,490
+120% +$3.05M ﹤0.01% 2732
2020
Q3 		$3.59M Sell
468,313
-31,918
-6% -$279K ﹤0.01% 2825
2020
Q2 		$5.01M Buy
500,231
+403,494
+417% +$2.53M ﹤0.01% 2458
2020
Q1 		$264K Buy
96,737
+20,531
+27% +$68.1K ﹤0.01% 4151
2019
Q4 		$91K Sell
76,206
-240,623
-76% -$257K ﹤0.01% 4933
2019
Q3 		$478K Buy
316,829
+38,709
+14% +$90.5K ﹤0.01% 4196
2019
Q2 		$1.11M Sell
278,120
-124,234
-31% -$507K ﹤0.01% 3795
2019
Q1 		$1.73M Sell
402,354
-33,924
-8% -$158K ﹤0.01% 3431
2018
Q4 		$2.51M Buy
436,278
+287,753
+194% +$2.12M ﹤0.01% 3119
2018
Q3 		$2.01M Sell
148,525
-63,465
-30% -$665K ﹤0.01% 3463
2018
Q2 		$2.52M Buy
211,990
+26,330
+14% +$328K ﹤0.01% 3233
2018
Q1 		$2.08M Buy
185,660
+164,704
+786% +$1.44M ﹤0.01% 3246
2017
Q4 		$140K Buy
20,956
+11,352
+118% +$87.7K ﹤0.01% 4541
2017
Q3 		$78K Buy
9,604
+3,514
+58% +$21.9K ﹤0.01% 4365
2017
Q2 		$27K Sell
6,090
-14,500
-70% -$75.8K ﹤0.01% 4472
2017
Q1 		$113K Sell
20,590
-13,253
-39% -$58K ﹤0.01% 4276
2016
Q4 		$137K Buy
33,843
+12,756
+60% +$61.2K ﹤0.01% 4297
2016
Q3 		$149K Buy
+21,087
New +$161K ﹤0.01% 3768

Other funds holding ADAP

LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

JP Morgan Chase's ADAP Position: Q3 2025 in Review

JP Morgan Chase sold out of Adaptimmune Therapeutics (ADAP) in Q3 2025, closing a stake of 22,782 shares — an estimated $5.46K sold.

JP Morgan Chase first reported a position in ADAP in Q3 2016 and held it in 36 quarters. The position peaked at $8.95M in Q1 2021. 55 funds tracked by Wall St. Rank hold ADAP as of Q3 2025.

  • JP Morgan Chase reported no remaining Adaptimmune Therapeutics position as of Q3 2025 after selling out during the quarter.
  • JP Morgan Chase sold 22,782 Adaptimmune Therapeutics shares in Q3 2025, an estimated $5.46K.
  • JP Morgan Chase first reported a position in Adaptimmune Therapeutics in Q3 2016 and held it in 36 quarters.
  • JP Morgan Chase's Adaptimmune Therapeutics position peaked at $8.95M in Q1 2021.
  • 55 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2025.

Based on JP Morgan Chase's 13F filing for Q3 2025, filed 7 Nov 2025.